Tripril monoclonal antibody

In the last two weeks of April, 4 innovative drugs are expected to be approved in the United States, of which 2 are domestic
Innovative medicine Obstructive hypertrophic cardiomyopathy mavacamten Bristol-Myers Squibb fda Tripril monoclonal antibody has and Huang Medicine Sofatinib Pancreatic neuroendocrine tumor
04-17
In the next 3 weeks, 4 innovative drugs are expected to be approved by the FDA| Bilingual
fda Obstructive hypertrophic cardiomyopathy Tripril monoclonal antibody mavacamten pdufa
04-09
Myth shattered, Junshi PD-1 sales fell by 60%, soul bargaining does not back the pot
pd-1 Junshi Tripril monoclonal antibody Junshi Creatures AstraZeneca
04-01
Heavy! Immunotherapy for advanced esophageal cancer in China refreshes the longest survival
Tripril monoclonal antibody Esophageal carcinoma immunity Esophageal squamous cell carcinoma chemotherapy
03-06
Major breakthrough! Chinese experts will rewrite the global model of treatment for advanced esophageal cancer
Esophageal carcinoma Tripril monoclonal antibody Xu Ruihua Esophageal squamous cell carcinoma chemotherapy
03-05
The effect of combination immunotherapy for nasopharyngeal carcinoma is "amazing", and tripramide is included in the new version of the medical insurance directory
Tripril monoclonal antibody Nasopharyngeal carcinoma Metastatic nasopharyngeal carcinoma chemotherapy Junshi Creatures
01-26
Chemotherapy + immunotherapy for nasopharyngeal carcinoma greatly prolongs the survival of advanced patients
Nasopharyngeal carcinoma Tripril monoclonal antibody chemotherapy Cancer Prevention and Treatment Center, Sun Yat-sen University Mai Haiqiang
01-24